## Gates Institute Cell and Gene Therapy



roduct Pipeline	Preclinical	IND-Enabling	Phase I Clinical Tria
Current Products			
CD19 CAR T: blood cancers  Adult relapsed/refractory (R/R) B-Cell Non-Hodgkin's Lymphoma (B-NHL)  Adult B-Cell Acute Lymphoblastic Leukemia (B-ALL)  Pediatric Relapsed/Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (B-ALL)  Pediatric Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL)			
CD19x22 CAR T: blood cancers  Adult relapsed/refractory (R/R) B-Cell Non-Hodgkin's Lymphoma (B-NHL)  Pediatric Relapsed/Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (B-ALL)			
CD19 CAR T: autoimmune disease  Adolescent Refractory Lupus Nephritis (LN)  Adolescent pJIA with Severe Refractory Disease Course			
Pipeline Immune Effector Cell (IEC) Products			
CART: acute myeloid leukemia (AML)			
CART: solid tumors			
CART: brain tumors			
Engineered tumor-infiltrating lymphocytes (TILs): solid tumors			
Pipeline iPSC Products			
iPSC: age-related macular degeneration (AMD)			
IPSC: epidermolysis bullosa (EB)			